Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive

NCT07063329 | Not Yet Recruiting Phase 1

• 1 other identifier: PLB1004 +Chemo-NSCLC-Ib/II-01
• Study Type: interventional
• Target: 108
• Locations: 1 country
• Sites: 1

Brief Summary

Tyrosine Kinase Inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with EGFR-TKI, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance develops are not fully understood but based upon clinical research it is hoped that combining PLB1004 with another type of anti-cancer therapy known as chemotherapy will delay the onset of resistance and the worsening of a patient's cancer. In recent years, clinical studies on the combination of EGFR-TKI and chemotherapy have made important progress, suggesting that the combination of EGFR-TKI and chemotherapy further enhances the therapeutic benefit in EGFR-mutant positive NSCLC. Both preclinical and clinical data indicate that PLB1004 exhibit good antitumor activity and relatively durable efficacy in NSCLC patients with EGFR mutations. They can reduce tumor burden, control tumor progression, and improve the survival benefit of patients, which is expected to provide an effective treatment option for such patients.

Conditions

NSCLC (Non-small Cell Lung Cancer)

Outcome Measures

Primary Outcomes (6)

• Phase Ib： Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])

  To evaluate the tolerability and safety of PLB1004 combined with platinum-based doublet chemotherapy in patients with epidermal growth factor receptor (EGFR) mutation positive NSCLC

  12 months

• Phase Ib： Incidence of dose-limiting toxicities (DLT) as defined in the protocol

  To determine the maximum tolerated dose (MTD) and/or dose-limiting toxicities (DLT) of combination therapy of PLB1004 combined with platinum-based doublet chemotherapy in patients with EGFR mutation positive NSCLC

  12 months

• Phase Ib： Recommended Phase II Dose (RP2D)

  To determine the recommended phase II dose (RP2D) of PLB1004 in combination with platinum-based doublet chemotherapy in subjects with EGFR mutation positive NSCLC

  12 months

• Phase Ib： Overall Response Rate (ORR）

  ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1

  24 months

• Phase II： To evaluate the efficacy of PLB1004 in combination with platinum-based doublet chemotherapy at the RP2D in subjects with EGFR mutation positive locally advanced or metastatic NSCLC

  Objective response rate (ORR) as evaluated by the investigator according to RECIST v1.1

  36 months

• Phase II： To evaluate the efficacy of PLB1004 in combination with platinum-based doublet chemotherapy at the RP2D RP2D in newly diagnosed resectable stage II-III NSCLC subjects with EGFR mutation positive

  Major pathological response (MPR) evaluated by the blinded independent pathology review committee (BIPR)

  12 months

Secondary Outcomes (13)

• Cmax

  12 months

• DOR

  36 months

• PFS

  36 months

• Tmax

  12 months

• (AUC0-t）

  12 months

Study Arms (4)

phase Ib Dose Escalation

EXPERIMENTAL

Drug: PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy

phase Ib Dose Expansion

EXPERIMENTAL

Drug: PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy

phase II Cohort1

EXPERIMENTAL

Drug: RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy

phase II Cohort2

EXPERIMENTAL

Drug: RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy

Interventions

PLB1004 80mg/160mg/240mg oral once daily Combined with Platinum-Based Chemotherapy DRUG

For non-squamous NSCLC patients：Pemetrexed (500 mg/m2) plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily。 For squamous NSCLC subjects: Docetaxel（75 mg/m² ）or paclitaxel（175 mg/mg） plus carboplatin (AUC5) or cisplatin（75 mg/m²）on Day 1 of 21day cycles (every 3 weeks) , followed by PLB1004 80mg/160mg/240mg oral once daily.

phase Ib Dose Escalation

RP2D of PLB1004 oral once daily Combined with Platinum-Based Chemotherapy DRUG

RP2D of PLB1004 as determined during Phase Ib . Platinum-based chemotherapy is combined and administered on Day 1 of 21days（every 3 weeks）.

phase II Cohort1

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Phase Ib Dose-escalation Part : Patients with histologically or cytologically confirmed unresectable locally advanced (stage IIIB and IIIC) or metastatic (stage IV) NSCLC (according to the eighth edition of the AJCC lung cancer staging criteria) who have disease progression or intolerance after previous systemic treatment. Specific treatment requirements are as follows:
• Patients with EGFR sensitive mutations: They must have received EGFR-TKI treatment. If only first/second-generation EGFR-TKIs were used, T790M negativity must be confirmed.
• Patients with other EGFR mutations such as EGFR exon 20 insertion: They must have received platinum-based chemotherapy.
• Phase Ib Dose-expansion part and Cohort 1 of Phase II: Patients with histologically or cytologically confirmed unresectable locally advanced (stage IIIB and IIIC) or metastatic (stage IV) NSCLC (according to the eighth edition of AJCC staging) who have not received previous systemic treatment or have received systemic treatment.
• Cohort 2 of Phase II: Patients with histologically confirmed resectable stage II-III NSCLC (according to the eighth edition of AJCC staging) who have not received previous systemic treatment; among them, N2 is defined as single-station mediastinal lymph node non-bulky metastasis (lymph node short diameter \<2 cm) confirmed by imaging and pathology, with expected complete resection.
• \. Previous tumor tissue or pleural effusion or blood sample confirmed positive for EGFR mutation.
• \. Measurable lesions at baseline according to RECIST 1.1 criteria.
• \. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
• \. Estimated life expectancy is more than 12 weeks.
• \. It has been medically evaluated and determined that the organ functions are good (within 7 days before the first study drug administration), including:
• hematological : absolute neutrophil count (ANC) ≥ 1.5 × 109/L, hemoglobin ≥ 90 g/L, platelets ≥ 100 × 109/L. Platelet transfusion is not allowed within 3 days before testing, red blood cell transfusion is not allowed within 14 days before testing, and hematopoietic growth factor therapy is not allowed within 7 days before testing (pegylated granulocyte colony-stimulating factor \[G-CSF\] or erythropoietin \[EPO\] is within 14 days before testing).
• liver function: serum TBIL ≤ 1.5×ULN (in patients with known Gilbert syndrome, TBIL ≤ 3×ULN and direct bilirubin \[DBIL\] ≤ 1.5×ULN), serum ALT/AST ≤ 2.5×ULN (for patients with confirmed liver metastases, ≤ 5.0×ULN).
• Renal function: Creatinine clearance ≥ 50 mL/min.
• coagulation function, defined as (including during anticoagulant therapy): prothrombin time (PT)\<1.5 × ULN, activated partial thromboplastin time (APTT)\<1.5 × ULN. If the subject is receiving anticoagulant therapy, they must receive a stable dose of anticoagulant at least one month prior to the first study administration.
• \. For cohort 2 of phase II: According to the surgeon's assessment, the total lung function can tolerate the planned pulmonary resection surgery.

You may not qualify if:

• \. Participated in other therapeutic clinical trials within 28 days prior to the first dose。
• \. Patients underwent major organ surgery within 4 weeks prior to the first dose.or is expected to undergo major surgery during the study.
• \. Have received lung field or whole-brain radiotherapy within 28 days before the first study drug administration, or has received palliative local radiotherapy within 14 days before the first dose。
• \. Patients received antitumour traditional Chinese medicine within 1 weeks prior to the first dose，and received local anti-tumor drug therapy (such as thoracic or abdominal perfusion, etc.) within 14 days or within 5 half-lives (whichever is shorter)。
• \. Patients with malignancies other than tumors treated in this study (except: malignancies that are cured and have not recurred within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of any type).
• \. Adverse effects of previous anti-tumor therapy have not recovered to CTCAE 5.0 grade rating of ≤ grade 1 (except for toxicity judged by the investigator be of no safety risk, such as alopecia, skin pigmentation, etc.)
• \. Have received systemic administration of potent inhibitors/inducers of CYP3A4 within 7 days prior to the first dose of treatment/randomization or are expected to receive systemic administration of these drugs during study treatment.
• \. Patients have symptomatic central nervous system (CNS) metastases, meningeal metastases, or a primary CNS tumor that is associated with progressive neurological symptoms.
• \. Patients have a history of severe cardiovascular disease, including but not limited to:
• Mean QT interval corrected using Fridericia's formula (QTcF) from three times\> 480ms at rest.
• New York Heart Association (NYHA) ≥ class II heart failure or left ventricular ejection fraction (LVEF) \< 50%.
• \. Hypertension remains uncontrolled（systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg ） after aggressive antihypertensive therapy.
• \. Patients with active uncontrolled systemic bacterial, viral, or fungal infection despite optimal treatment Active hepatitis (Hepatitis B: HBsAg-positive and HBV-DNA ≥ 2000 IU/ mL; Hepatitis B: HCV antibody-positive , HIV antibody-positive; Active syphilis, the onset period of keratitis or ulcerative keratitis.
• \. Patients are unable to swallow the drug orally, or has a condition that seriously affects gastrointestinal absorption in the judgment of the investigator.

Sponsors & Collaborators

• Avistone Pharmaceutical（Ningbo）Co., LTD.: lead

Study Sites (1)

Shanghai Chest hospital

Shanghai, China

Location

MeSH Terms

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

Platinum Compounds

Condition Hierarchy (Ancestors)

Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Intervention Hierarchy (Ancestors)

Inorganic Chemicals

Study Officials

• Shun Lu M.D, Ph.D.

  Shanghai Chest Hospital

  PRINCIPAL INVESTIGATOR

• Deng Hou Master

  Avistone Pharmaceutical（Ningbo）Co., LTD.

  STUDY DIRECTOR

Central Study Contacts

Shun Lu M.D, Ph.D.

CONTACT

86-21-22200000; shunlu@sjtu.edu.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 24, 2025
• First Posted: July 14, 2025
• Study Start: August 8, 2025
• Primary Completion (Estimated): March 8, 2028
• Study Completion (Estimated): July 8, 2028
• Last Updated: July 25, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)